ID

16460

Description

Safety Study of BLP25 Liposome Vaccine in Non-Small Cell Lung Cancer Patients With Unresectable Stage III Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00157196

Link

https://clinicaltrials.gov/show/NCT00157196

Keywords

Versions (1)
  1. 7/17/16 7/17/16 -
Uploaded on

July 17, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Non-Small-Cell Lung NCT00157196

English

Eligibility Carcinoma, Non-Small-Cell Lung NCT00157196

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically documented unresectable stage iii nsclc. mediastinal (n2) involvement must be confirmed by biopsy
Description

NSCLC

Data type

boolean

Alias
UMLS CUI [1]
C0007131
stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage iii disease
Description

stable disease or clinical response after primary therapy of chemo-radiation treatment

Data type

boolean

Alias
UMLS CUI [1]
C0677946
UMLS CUI [2,1]
C4055223
UMLS CUI [2,2]
C0436307
primary therapy should be a minimum of 2 cycles of platinum-based first-line chemotherapy, given concurrent with thoracic radiation. the combined modality should consist of either:
Description

Therapeutic procedure

Data type

boolean

Alias
UMLS CUI [1]
C0087111
induction (2 cycles) chemotherapy followed by concurrent chemo/rt; or
Description

Concurrent Therapy

Data type

boolean

Alias
UMLS CUI [1]
C0009429
concurrent chemo/rt followed by 2 cycles of consolidation chemotherapy; or
Description

Concurrent Therapy

Data type

boolean

Alias
UMLS CUI [1]
C0009429
concurrent chemo/rt alone
Description

Concurrent Therapy

Data type

boolean

Alias
UMLS CUI [1]
C0009429
a minimum radiation dose of ≥6,000cgy should be administered. patients must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry
Description

Radiation dosage

Data type

boolean

Alias
UMLS CUI [1]
C0034620
ecog performance status of ≤1
Description

ECOG

Data type

boolean

Alias
UMLS CUI [1]
C1520224
ability to understand and willingness to sign a written informed consent
Description

written informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
undergone lung cancer specific therapy (including surgery) prior to primary chemo/rt
Description

Prior lung cancer specific therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0242379
received immunotherapy within 4 weeks prior to study entry
Description

Prior immunotherapy

Data type

boolean

Alias
UMLS CUI [1]
C0021083
received systemic immunosuppressive drugs within 4 weeks prior to study entry
Description

Systemic immunosuppressive agents

Data type

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205373
received investigational systemic drugs within 4 weeks prior to study entry
Description

Investigational systemic drug

Data type

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0205373
brain metastases
Description

Brain metastases

Data type

boolean

Alias
UMLS CUI [1]
C0220650
pleural effusion, unless cytologically confirmed to be non-malignant
Description

Malignant pleural effusion

Data type

boolean

Alias
UMLS CUI [1]
C0080032
past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
Description

Neoplasm

Data type

boolean

Alias
UMLS CUI [1]
C0027651
autoimmune disease or immunodeficiency
Description

Autoimmune disease or immunodeficiency

Data type

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2]
C0021051
clinically significant hepatic, renal or cardiac dysfunction
Description

Hepatic, renal or cardiac dysfunction

Data type

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232164
clinically significant active infection
Description

Infection

Data type

boolean

Alias
UMLS CUI [1]
C0009450
pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator
Description

pregnant or lactating, women of childbearing potential

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C3831118
Back to the top of the page

Similar models

Eligibility Carcinoma, Non-Small-Cell Lung NCT00157196

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
NSCLC
Item
histologically documented unresectable stage iii nsclc. mediastinal (n2) involvement must be confirmed by biopsy
boolean
C0007131 (UMLS CUI [1])
stable disease or clinical response after primary therapy of chemo-radiation treatment
Item
stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage iii disease
boolean
C0677946 (UMLS CUI [1])
C4055223 (UMLS CUI [2,1])
C0436307 (UMLS CUI [2,2])
Therapeutic procedure
Item
primary therapy should be a minimum of 2 cycles of platinum-based first-line chemotherapy, given concurrent with thoracic radiation. the combined modality should consist of either:
boolean
C0087111 (UMLS CUI [1])
Concurrent Therapy
Item
induction (2 cycles) chemotherapy followed by concurrent chemo/rt; or
boolean
C0009429 (UMLS CUI [1])
Concurrent Therapy
Item
concurrent chemo/rt followed by 2 cycles of consolidation chemotherapy; or
boolean
C0009429 (UMLS CUI [1])
Concurrent Therapy
Item
concurrent chemo/rt alone
boolean
C0009429 (UMLS CUI [1])
Radiation dosage
Item
a minimum radiation dose of ≥6,000cgy should be administered. patients must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry
boolean
C0034620 (UMLS CUI [1])
ECOG
Item
ecog performance status of ≤1
boolean
C1520224 (UMLS CUI [1])
written informed consent
Item
ability to understand and willingness to sign a written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior lung cancer specific therapy
Item
undergone lung cancer specific therapy (including surgery) prior to primary chemo/rt
boolean
C1514463 (UMLS CUI [1,1])
C0242379 (UMLS CUI [1,2])
Prior immunotherapy
Item
received immunotherapy within 4 weeks prior to study entry
boolean
C0021083 (UMLS CUI [1])
Systemic immunosuppressive agents
Item
received systemic immunosuppressive drugs within 4 weeks prior to study entry
boolean
C0021081 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Investigational systemic drug
Item
received investigational systemic drugs within 4 weeks prior to study entry
boolean
C0013230 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Brain metastases
Item
brain metastases
boolean
C0220650 (UMLS CUI [1])
Malignant pleural effusion
Item
pleural effusion, unless cytologically confirmed to be non-malignant
boolean
C0080032 (UMLS CUI [1])
Neoplasm
Item
past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
boolean
C0027651 (UMLS CUI [1])
Autoimmune disease or immunodeficiency
Item
autoimmune disease or immunodeficiency
boolean
C0004364 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
Hepatic, renal or cardiac dysfunction
Item
clinically significant hepatic, renal or cardiac dysfunction
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232164 (UMLS CUI [3])
Infection
Item
clinically significant active infection
boolean
C0009450 (UMLS CUI [1])
pregnant or lactating, women of childbearing potential
Item
pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial